Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 6/20 | 0.59 |
| ▸ | SYK | P43405 | 8/20 | 0.53 |
| ▸ | JAK1 | P23458 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | TYK2 | P29597 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | STK25 | O00506 | 1/20 | 0.42 |
| ▸ | CIT | O14578 | 1/20 | 0.42 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525441 | 1.00 | NR3C2 (0.59) | NR3C2SYKJAK1JAK3JAK2 | |
| SCHEMBL2517922 | 0.91 | NR3C2 (0.54) | NR3C2SYKJAK1JAK3JAK2 | |
| SCHEMBL12213063 | 0.91 | NR3C2 (0.54) | NR3C2SYKJAK1JAK3JAK2 | |
| SCHEMBL2519967 | 0.91 | SYK (0.56) | NR3C2SYKJAK1JAK3JAK2 | |
| SCHEMBL2519964 | 0.91 | SYK (0.56) | NR3C2SYKJAK1JAK3JAK2 | |
| SCHEMBL2519219 | 0.89 | SYK (0.56) | NR3C2SYKJAK1JAK3JAK2 | |
| SCHEMBL12213090 | 0.88 | SYK (0.52) | NR3C2SYKJAK1JAK3JAK2 | |
| SCHEMBL12213088 | 0.88 | SYK (0.52) | NR3C2SYKJAK1JAK3JAK2 | |
| SCHEMBL2524918 | 0.88 | SYK (0.57) | NR3C2SYKJAK1JAK3JAK2 | |
| SCHEMBL12212876 | 0.88 | SYK (0.57) | NR3C2SYKJAK1JAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558474-B1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-11-25 | — | — | EP | claimed |
| US-8618095-B2 | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-12-31 | — | — | US | claimed |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | claimed |
| EP-2558474-B1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-11-25 | — | — | EP | disclosed |
| US-8618095-B2 | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2558474-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130390-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | TYMP, DPYD, TYMS | NR3C2 4364/4885SYK 1871/4885JAK1 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.